Trials / Completed
CompletedNCT00351923
Immunogenicity/Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA): Using Two Different Administration Routes
Open, Multicenter, Randomised, Controlled Phase IIIb Study Evaluating the Immunogenicity and Safety of Subcutaneous Versus Alternative Administration Route of Combined MeMuRu-OKA Vaccine to Healthy Children Aged 11 to 21 Months.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 330 (planned)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 11 Months – 22 Months
- Healthy volunteers
- Accepted
Summary
This study will compare the immunogenicity and safety of the MeMuRu-OKA vaccine administered subcutaneously or using an alternative administration route.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MeMuRu-OKA (study vaccine) |
Timeline
- Start date
- 2006-03-01
- Completion
- 2006-12-01
- First posted
- 2006-07-13
- Last updated
- 2008-10-13
Locations
20 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT00351923. Inclusion in this directory is not an endorsement.